The estimated Net Worth of Charles J Casamento is at least $1.96 Million dollars as of 9 September 2024. Mr. Casamento owns over 13,000 units of Relmada Therapeutics Inc stock worth over $39,260 and over the last 17 years he sold RLMD stock worth over $1,379,052. In addition, he makes $541,931 as Independent Chairman of the Board at Relmada Therapeutics Inc.
Charles has made over 26 trades of the Relmada Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 13,000 units of RLMD stock worth $33,280 on 9 September 2024.
The largest trade he's ever made was exercising 67,578 units of Relmada Therapeutics Inc stock on 24 December 2019 worth over $247,335. On average, Charles trades about 4,620 units every 70 days since 2008. As of 9 September 2024 he still owns at least 13,000 units of Relmada Therapeutics Inc stock.
You can see the complete history of Mr. Casamento stock trades at the bottom of the page.
Charles J. Casamento serves as Independent Chairman of the Board of the Company since June 2017 and a director since July 2015. Mr. Casamento is also a member of our Audit Committee, Compensation Committee, and Corporate Governance and Nominating Committee. Since 2007 Mr. Casamento has been Executive Director and Principal of The Sage Group, a health care advisory group specializing in business development strategies and transactions. Prior to The Sage Group he was President and CEO of Osteologix from October 2004 until April 2007. Originally a private VC funded company in Copenhagen, Denmark which had discovered a new drug for the treatment of Osteoporosis, Mr. Casamento commenced operations and initiated clinical trials in the US, completed a financing and took the company public through a merger with a public shell company. The product was eventually acquired by Servier a major French pharmaceutical company. Osteologix was Mr. Casamento’s fifth startup company, all of which were successfully taken public, during his tenure, either through IPOs or through reverse mergers. Mr. Casamento currently serves as an Independent Director for AzurRx Biopharma. During his career he has served on the boards of twelve public companies and two private companies. Mr. Casamento also served as Chairman of the Audit Committee of Astex Pharmaceuticals and is a SOX defined financial expert. He is a member of the Fordham University Science Council and has been a guest lecturer at Fordham University. He was previously Vice Chairman of the Catholic Medical Mission Board, a large not for profit organization providing health care services to third world countries. A graduate of Fordham University in New York City and Iona College in New Rochelle, New York. Mr. Casamento has a degree in Pharmacy and an MBA.
As the Independent Chairman of the Board of Relmada Therapeutics Inc, the total compensation of Charles Casamento at Relmada Therapeutics Inc is $541,931. There are 4 executives at Relmada Therapeutics Inc getting paid more, with Sergio Traversa having the highest compensation of $1,236,360.
Charles Casamento is 75, he's been the Independent Chairman of the Board of Relmada Therapeutics Inc since 2017. There are no older and 15 younger executives at Relmada Therapeutics Inc.
Charles's mailing address filed with the SEC is C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES, FL, 33134.
Over the last 6 years, insiders at Relmada Therapeutics Inc have traded over $1,379,052 worth of Relmada Therapeutics Inc stock and bought 574,305 units worth $1,722,071 . The most active insiders traders include Sergio Traversa, Charles J Casamento und Paul Edward Kelly. On average, Relmada Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $54,221. The most recent stock trade was executed by Sergio Traversa on 9 September 2024, trading 140,000 units of RLMD stock currently worth $394,800.
relmada therapeutics (otcqb: rlmd) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. relmada has a diversified portfolio of four lead products at various stages of development including d-methadone (rel-1017) its n-methyl-d-aspartate (nmda) receptor antagonist for neuropathic pain; topical mepivacaine (rel-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (rel-1028) its oral dosage form of the opioid analgesic buprenorphine; and levocap er (rel-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. relmada’s approach is expected to reduce clinical development risks and
Relmada Therapeutics Inc executives and other stock owners filed with the SEC include: